ROTHBLATT MARTINE A sold $5.0M of UTHR (indirect holdings)
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $522.57 ($511.58–$531.12, $4.96M total) across 18 trades on 2026-08-27 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale adds new information about insider activity, which can influence short‑term trading decisions.
Market read
First‑report insider sale provides fresh data for traders monitoring United Therapeutics.
What to watch
Potential upcoming clinical trial data or regulatory news could be the real driver of price movement.
Background
SEC Form 4 filing discloses insider transactions required by law.
Ticker impact
CEO Martine Rothblatt sold $5.0M of United Therapeutics shares via a 10b5‑1 plan on 2026‑08‑27.
Possible modest dip of 1‑2% over the next few days.
Large insider sell by the chairperson, though pre‑arranged, often leads to temporary sell pressure.
Market effects
Minimal impact on the biotech sector; only a single insider transaction.
U.S. market only; no broader regional effect.
Low; limited to United Therapeutics investors.
Counterpoint
The sale was pre‑arranged under a 10b5‑1 plan, so it may not reflect a change in confidence.
Key entities
- CompanyUnited Therapeutics Corp
Biopharmaceutical company focused on pulmonary arterial hypertension.
- ExecutiveMartine A. Rothblatt
Chairperson & CEO of United Therapeutics.
